[Flucytosine in the treatment of urinary fungal infections. Clinical efficacy and background factors].
Flucytosine (5-FC), an oral antifungal agent, was used in the treatment of 37 patients with urinary tract infections due to fungi. Criteria for treatment included pyuria of greater than or equal to 5 WBCs/HPF, fungal colony counts in urine greater than 10(3) CFU/ml and the presence of candiduria in 2 consecutive urine culture with interval of 7 days. Patients received 2 approximately 8 g/day of 5-FC for 7 to 14 days. The clinical efficacy was evaluated in 27 patients with 14 day-treatment and overall efficacy rate was 77.8%. In patients with indwelling catheter, overall efficacy rate was lower than that in patients without catheter. Twenty-two of 30 strains (73.3%) were eradicated by the treatment. The MIC of 5-FC for isolates was less than 0.78 micrograms/ml except for 5 strains. The secondary resistance during 5-FC treatment was observed in early phase in 6 patients whose clinical efficacy was poor. The loss of appetite and mild leukocytopenia were observed as adverse effects. From the results of our study, 5-FC appears to be effective and safe in the treatment of urinary tract infection due to fungi.
Fujihiro
S
S
Department of Urology, School of Medicine, Gifu University.
Ehara
H
H
Saito
A
A
Ito
Y
Y
Kanematu
M
M
Ban
Y
Y
Kawada
Y
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002175:Candida / Q000302:isolation & purification; D005260:Female; D005437:Flucytosine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology
D005437:Flucytosine